ICMR - NIRBI


ICMR - National Institute for Research
in Bacterial Infections

आईसीएमआर - राष्ट्रीय जीवाणु संक्रमण अनुसंधान संस्थान

Department of Health Research, Ministry of Health and Family Welfare, Government of India
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य और परिवार कल्याण मंत्रालय, भारत सरकार
WHO Collaborating Centre For Research and Training On Diarrhoeal Diseases

BETI BACHAO BETI PADHAO
G20

  English   |   हिंदी           

NICED : Scientists

  1. NICED
  2. Scientists
Dr. Moumita Bhaumik Ghosh

Dr. Moumita Bhaumik

 

General Information
Name Dr. Moumita Bhaumik
Designation Scientist D
Educational Qualification Ph.D.
Date of joining ICMR 06 November 2017
Date of joining present post 20 June 2023
Discipline Immunology
Email moumita.bh@icmr.gov.in ; drmoumitabhaumik@gmail.com
Academic Qualification :  
Graduation B. Sc in Zoology (2004)
Post Graduation M.Sc in Biophysics and Molecular Biology (2006)
Doctoral PhD inBiophysics and Molecular Biology (2014)

Profile

Research Experience

With a previous experience in the immunobiology of Leishmania infection, I joined NIRBI and focused my research on gut immunology. We established colitis model in mice started exploring possibilities of immune regulation of RNA binding proteins. In this regard we have successfully developed morpholino induced knockdown model in mice to address research questions. With the change in mandate of research activities in NIRBI our lab is trying to focus we are trying to utilize our research experiences and address the new research questions.
 

Research Interest

RNA-binding proteins critically influence gene expression programs in physiology and disease. Towards the long-term goal of uncovering post-transcriptional regulatory mechanisms in regulating the physiology of gut during Inflammatory Bowel Disease (IBD) and arsenic toxicity, we use primary cells, cell lines, mice model and human colon organoids to study specific RNA-driven processes that control (1) immune responses, (2) gut barrier function, and (3) EMT responses. We undertake studies to determine therapeutic role of novel antisense technology and/or per rectal treatment with modified organoids in mice IBD model.

In the context with the change in institute's mandate of research we also focus in developing immunotherapies and vaccines for anti-microbial resistant bacteria.

Membership/ Fellow of Professional Societies/ Associations

  1. Life member of 1. Society for Biological Sciences,
  2. Calcutta Consortium for Human Genomics

Awards

  1. A. K. Memorial Award for first in B.Sc in University of Calcutta 2004.
  2. CEFIPRA PROWIS-I Women fellowship 2023
  3. IIS - Women in Science Recognition 2024

 

Projects:

Extramural

# Project title Funding agency Period
1 Novel cell penetrating Phosphorodiamidate Morpholino Oligomer based therapy for IBD targeting sphingosine kinase1 DHR2 2024 - 2027
2 Comparative assessment of immune responses following covaxin, covishield, sputnik-V and development of a novel vaccine candidate using doggybone/ (MIDGE) DNA encoding SARSCoV2- spike protein for employing alongside current vaccines in heterologous prime-boost approach in mice ICMR extramural 2022 - 2025
3 Assessment of prophylactic and therapeutic role of BCG against SARS CoV2 infection: study in hamster model DBT-BIRAC2 2021 - 2022
4 Sphingolipid as mediator in the interface of microbiome and host: implication in gut pathology DST-SERB 2021 - 2024

 

Intramural

# Project title Period
1 Designing morpholino oligonucleotides (MO) based therapeutic for inflammatory bowel disease and its functional analysis 2024 - 2027
2 The role of short chain fatty acid in cholesterol homeostasis: implication in gut immunology 2018 - 2022

 

Students

  • JRF: Sutanu Acharya Chowdhury, Diganta Roy
  • SRF: Aaheli Masid
  • RA
  • PDF: Oishika Das

     

Publications

Publications in NIRBI

  1. Sikdar S, Mitra D, Das O, Bhaumik M, Dutta S. The functional antagonist of sphingosine-1-phosphate, FTY720, impairs gut barrier function. Front Pharmacol. 2024;15:1407228.
    2. Das O, Masid A, Chakraborty M, Gope A, Dutta S, Bhaumik M. Butyrate driven raft disruption trots off enteric pathogen invasion: possible mechanism of colonization resistance. Gut Pathog. 2023;15(1):19.
  2. Das O, Kundu J, Ghosh A, Gautam A, Ghosh S, Chakraborty M, et al. AUF-1 knockdown in mice undermines gut microbial butyrate-driven hypocholesterolemia through AUF-1-Dicer-1-mir-122 hierarchy. Front Cell Infect Microbiol. 2022;12:1011386.
  3. Nickla DL, Wang X, Rucker F, Chen W, Taylor C. Effects of Morning or Evening Narrow-band Blue Light on the Compensation to Lens-induced Hyperopic Defocus in Chicks. Optom Vis Sci. 2023;100(1):33-42.
  4. Alcantara LCJ, Amenga-Etego L, Andersson R, Bhaumik M, Choi YK, Decaluwe H, et al. Methods for fighting emerging pathogens. Nat Methods. 2022;19(4):395-7.
  5. Chakraborty M, Bhaumik M. Prenatal arsenic exposure interferes in postnatal immunocompetence despite an absence of ongoing arsenic exposure. J Immunotoxicol. 2020;17(1):135-43.

Publications before joining NICED

  1. Ghosh M, Roy K, Das Mukherjee D, Chakrabarti G, Roy Choudhury K, Roy S. Correction: Leishmania donovani Infection Enhances Lateral Mobility of Macrophage Membrane Protein Which Is Reversed by Liposomal Cholesterol. PLoS Negl Trop Dis. 2016;10(4):e0004640.
  2. Ghosh M, Solanki AK, Roy K, Dhoke RR, Ashish, Roy S. Carrier protein influences immunodominance of a known epitope: implication in peptide vaccine design. Vaccine. 2013;31(41):4682-8.
  3. Ghosh M, Roy K, Roy S. Immunomodulatory effects of antileishmanial drugs. J Antimicrob Chemother. 2013;68(12):2834-8.
  4. Roy K, Ghosh M, Pal TK, Chakrabarti S, Roy S. Cholesterol lowering drug may influence cellular immune response by altering MHC II function. J Lipid Res. 2013;54(11):3106-15.
  5. Roy K, Naskar K, Ghosh M, Roy S. Class II MHC/peptide interaction in Leishmania donovani infection: implications in vaccine design. J Immunol. 2014;192(12):5873-80.
  6. Bhattacharya P, Gupta G, Majumder S, Adhikari A, Banerjee S, Halder K, et al. Arabinosylated lipoarabinomannan skews Th2 phenotype towards Th1 during Leishmania infection by chromatin modification: involvement of MAPK signaling. PLoS One. 2011;6(9):e24141.
  7. Banerjee S, Ghosh J, Sen S, Guha R, Dhar R, Ghosh M, et al. Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells. Infect Immun. 2009;77(6):2330-42.